Keith Graham McCullagh
Chairman at Xention Pharma Ltd.
Net worth: 750 719 $ as of 29/04/2024
Profile
Keith Graham McCullagh is the founder of Ligand UK Ltd.
which was founded in 1986.
He held the position of Chief Executive Officer for a brief period in 1998.
Currently, he is the Chairman of Xention Pharma Ltd., Non-Executive Chairman of Metrion Biosciences Ltd., Director of Xention Ltd., and Director of Torpedo Factory Ltd.
He previously held the position of President & Chief Executive Officer at Roche Innovation Center Copenhagen A from 2003 to 2008.
He also served as Chairman of Affitech AS, Weifa ASA, The Bioindustry Association, Pharmacy2U Ltd., and ario pharma Ltd.
He was Vice Chairman of The European Association for Bioindustries.
He was an Independent Director at Affitech A from 2008 to 2012.
He also worked as a Research Director-United Kingdom at G.D.
Searle LLC.
Dr. McCullagh holds a doctorate degree from the University of Cambridge and an undergraduate degree from the University of Bristol.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
AUKETT SWANKE GROUP PLC
12.32% | 26/03/2023 | 41,339,142 ( 12.32% ) | 750 719 $ | 29/04/2024 |
Keith Graham McCullagh active positions
| Companies | Position | Start |
|---|---|---|
Xention Pharma Ltd.
 Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Chairman | - |
Metrion Biosciences Ltd.
 Metrion Biosciences Ltd. BiotechnologyHealth Technology Metrion Biosciences Ltd. is a contract research organization that specializes in providing drug discovery services to pharmaceutical and bioscience customers. Metrion Biosciences is based in Great Abington, UK and was founded in 2015. The British company offers a range of high-quality ion channel assays on a fee-for-service or collaboration basis, including an industry-leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Andrew Southan has been the CEO of the company since 2016. | Chairman | - |
Xention Ltd.
 Xention Ltd. Pharmaceuticals: MajorHealth Technology Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The company is based in Newmarket, UK. Xention was founded in 2002. | Director/Board Member | 28/10/2008 |
Torpedo Factory Ltd.
 Torpedo Factory Ltd. Information Technology ServicesTechnology Services Part of Aukett Swanke Group Plc, Torpedo Factory Ltd. is a British system integration company that provides professional and managed services for stage, audio visual, and intelligent environments. The company is based in London, UK. Founded in 1960. | Director/Board Member | 26/12/2001 |
Former positions of Keith Graham McCullagh
| Companies | Position | End |
|---|---|---|
Affitech A/S
 Affitech A/S Pharmaceuticals: MajorHealth Technology Affitech A/S engages in the development of human antibody therapeutics. It focuses on human antibodies for cancer such as hematological and solid tumors; and serious inflammatory conditions including rheumatoid arthritis and severe asthma. The firm enters into partnerships and collaborations with biotechnology companies for antibody discovery and development. The company was founded by Søren Mouritsen and Henrik Irgang Elsner on October 1, 1990 and is headquartered in Copenhagen, Denmark. | Director/Board Member | 26/04/2012 |
| WEIFA ASA | Chairman | 19/05/2010 |
Affitech AS /Old/
 Affitech AS /Old/ Miscellaneous Commercial ServicesCommercial Services Affitech AS discovers and develops human therapeutic antibodies. It focuses on molecule and cell based antibody discovery. The company was founded by Martin Welschof, Ole Jorgen Marvik, and Michael Braunagel in 1997 and is headquartered in Oslo, Norway. | Chairman | 15/06/2009 |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Chief Executive Officer | 30/06/2008 |
| VERNALIS | Chief Executive Officer | 31/12/1997 |
Training of Keith Graham McCullagh
| University of Cambridge | Doctorate Degree |
| University of Bristol | Undergraduate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 14 |
|---|---|
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Health Technology |
Affitech AS /Old/
Affitech AS /Old/ Miscellaneous Commercial ServicesCommercial Services Affitech AS discovers and develops human therapeutic antibodies. It focuses on molecule and cell based antibody discovery. The company was founded by Martin Welschof, Ole Jorgen Marvik, and Michael Braunagel in 1997 and is headquartered in Oslo, Norway. | Commercial Services |
Xention Pharma Ltd.
Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Health Technology |
The Bioindustry Association
 The Bioindustry Association Miscellaneous Commercial ServicesCommercial Services The BioIndustry Association is a UK-based organization that represents the life sciences and biotech industry. The British company's mission is to facilitate and connect the ecosystem to help businesses start, grow, and deliver world-changing innovation. The non-profit company was founded by Cormac G. Kilty and Simon Geoffrey Best, and Steve Bates has been the CEO of the company since 2012. | Commercial Services |
Pharmacy2U Ltd.
 Pharmacy2U Ltd. Drugstore ChainsRetail Trade Pharmacy2U Ltd. provides online pharmacy services. The firm offers private online doctors, NHS, private prescriptions, over-the-counter medicines, health, beauty products, fine fragrances, and skincare products. The company was founded by Daniel Mark Lee and Steven John Dobson on July 8, 1999 and is headquartered in Leeds, the United Kingdom. | Retail Trade |
Weifa ASA
 Weifa ASA Pharmaceuticals: MajorHealth Technology Weifa ASA engages in the development, production and sales of medicines and other health products. Its products include medicines for pain relief, cough and cold, nutraceuticals, and dermatology. The company was founded by Olaf Weider in 1940 and is headquartered in Oslo, Norway. | Health Technology |
Affitech A/S
Affitech A/S Pharmaceuticals: MajorHealth Technology Affitech A/S engages in the development of human antibody therapeutics. It focuses on human antibodies for cancer such as hematological and solid tumors; and serious inflammatory conditions including rheumatoid arthritis and severe asthma. The firm enters into partnerships and collaborations with biotechnology companies for antibody discovery and development. The company was founded by Søren Mouritsen and Henrik Irgang Elsner on October 1, 1990 and is headquartered in Copenhagen, Denmark. | Health Technology |
Ligand UK Ltd.
 Ligand UK Ltd. Pharmaceuticals: MajorHealth Technology Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1988 and is headquartered in Winnersh, the United Kingdom. | Health Technology |
| G.D. Searle LLC | |
| The European Association for Bioindustries | |
ario pharma Ltd.
 ario pharma Ltd. Pharmaceuticals: MajorHealth Technology ario pharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of respiratory indications. The company was founded by John Ford and Patrick M. Round in 2010 and is headquartered in Great Shelford, the United Kingdom. | Health Technology |
Metrion Biosciences Ltd.
Metrion Biosciences Ltd. BiotechnologyHealth Technology Metrion Biosciences Ltd. is a contract research organization that specializes in providing drug discovery services to pharmaceutical and bioscience customers. Metrion Biosciences is based in Great Abington, UK and was founded in 2015. The British company offers a range of high-quality ion channel assays on a fee-for-service or collaboration basis, including an industry-leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Andrew Southan has been the CEO of the company since 2016. | Health Technology |
Xention Ltd.
Xention Ltd. Pharmaceuticals: MajorHealth Technology Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The company is based in Newmarket, UK. Xention was founded in 2002. | Health Technology |
Torpedo Factory Ltd.
Torpedo Factory Ltd. Information Technology ServicesTechnology Services Part of Aukett Swanke Group Plc, Torpedo Factory Ltd. is a British system integration company that provides professional and managed services for stage, audio visual, and intelligent environments. The company is based in London, UK. Founded in 1960. | Technology Services |
- Stock Market
- Insiders
- Keith Graham McCullagh
